Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.62 |
| ▸ | PDE4A | P27815 | 9/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6585967 | 0.88 | PDE4B (0.65) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL5565347 | 0.86 | PDE4B (0.64) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL7329999 | 0.85 | PDE4D (0.80) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL4709683 | 0.85 | PDE4B (0.65) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL16806651 | 0.85 | PDE4B (0.51) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL27472680 | 0.84 | PDE4D (0.68) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL7340272 | 0.84 | PDE4D (0.78) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL5349155 | 0.84 | PDE4B (0.67) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL7441489 | 0.83 | PDE4B (0.63) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6587335 | 0.83 | PDE4B (0.80) | PDE4BPDE4DPDE4APDE4CMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-0832071-B1 | 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-28 | — | — | EP | disclosed |
| EP-0832071-A1 | 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-04-01 | — | — | EP | disclosed |
| WO-1998008844-A1 | THIAZOLE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE-IV | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-03-05 | — | — | WO | disclosed |
| WO-1996031487-A1 | 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | disclosed |
| EP-0538384-A4 | OXAMIDES | SMITHKLINE BEECHAM CORP (US) | 1995-04-12 | — | — | EP | disclosed |
| US-5393788-A | Phenylalkyl oxamides | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0538384-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000968-A1 | OXAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | PDE4B 3261/4885PDE4D 3827/4885PDE4A 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.